Marion Carafate advertising
The company met with FDA Division of Drug Advertising and Labeling on April 10 to discuss remedial actions that the agency requested in a March 14 reg letter. In objecting to Marion's continuing promotions that imply that Carafate is useful for NSAID-induced ulcers and other unapproved uses. FDA told the firm that it should send a corrective letter to every U.S. physician and run corrective ads in medical journals ("The Pink Sheet" March 27, p. 9).
You may also be interested in...
HBW editors Tom Gallen and David Ridley discuss the big issues in the European consumer health market from the past week. In this edition, they delve into probiotics, digital health and Bayer’s recent turnaround.
EU trade expert Hervé Jouanjean considers the reasoning behind the EU’s vaccine procurement approach and Italy's decision to block exports of AstraZeneca's COVID-19 vaccine.
Efforts are underway to create a harmonized approach among Persons Responsible for Regulatory Compliance who play a pivotal role in meeting the requirements of the EU MDR and IVDR. And liability issues are high on the agenda.